To identify key predictors of RFS in melanoma patients receiving IFN-α1b adjuvant therapy, we performed the time-dependent feature importance analysis, including tumor characteristics (site and stage), patient demographics (age and sex), comorbidities (diabetes mellitus, hypertension and hepatitis B virus) and various laboratory indices (neutrophil (NEU), alanine aminotransferase, aspartate aminotransferase, lymphocyte, hemoglobin (Hb), albumin (ALB), white blood cell, platelet and alkaline phosphatase) (Supplementary Figure 1). Here, GSTM1 is linked to melanoma.